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Background and aim Systematic analyses of inﬂammatory bowel disease (IBD) drug-related side effects necessitating
treatment cessation in large cohorts of patients with IBD are scarce. We aimed to assess the frequency and type of drug-related
side effects requiring drug cessation in patients included in the Swiss IBD Cohort.
Patients and methods A retrospective review was performed of data from the Swiss IBD Cohort physician questionnaires
documenting a treatment cessation for the following drug categories: aminosalicylates, topical and systemic steroids, thiopurines,
methotrexate, tumor necrosis factor-antagonists, and calcineurin inhibitors (tacrolimus, cyclosporine).
Results A total of 3192 patients were analyzed, of whom 1792 (56.1%) had Crohn’s disease, 1322 (41.4%) had ulcerative
colitis, and 78 (2.5%) had IBD unclassiﬁed. Of 3138 patients treated with IBD drugs, 2129 (67.8%) presented with one or several
drug-related side effects necessitating drug cessation. We found a signiﬁcant positive correlation between the number of
concomitantly administered IBD drugs and the occurrence of side effects requiring drug cessation (P< 0.001). Logistic regression
modeling identiﬁed Crohn’s disease diagnosis [odds ratio (OR)=1.361, P=0.017], presence of extraintestinal manifestations
(OR=2.262, P< 0.001), IBD-related surgery (OR= 1.419, P= 0.006), and the increasing number of concomitantly used IBD
drugs [OR=2.007 (P<0.001) for two concomitantly used IBD drugs; OR= 3.225 (P<0.001) for at least three concomitantly
used IBD drugs] to be associated signiﬁcantly with the occurrence of IBD drug-related adverse events that necessitated
treatment cessation.
Conclusion Physicians should keep in mind that the number of concomitantly administered IBD drugs is the main risk factor for
drug-related adverse events necessitating treatment cessation. Eur J Gastroenterol Hepatol 00:000–000
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) represent
the two main types of inﬂammatory bowel disease (IBD)
[1,2]. There is increasing evidence that IBD results from an
inappropriate inﬂammatory response to intestinal microbes
in a genetically susceptible host [1,2]. The majority of IBD
patients will suffer from a chronic disease course with the
development of tissue damage related to the long-standing
inﬂammatory activity [3]. As such, the vast majority of IBD
patients will need long-term anti-inﬂammatory treatments,
not only for short-term symptom control but also to reduce
the risk of subsequent bowel damage [4,5].
Inevitably, IBD drugs may also be associated with drug-
related side effects [6]. Examples include dermatological
complications such as the development of a paradoxical
psoriasiform skin reaction under tumor necrosis factor
(TNF)-antagonist therapy or an increased risk of non-
melanomatous skin cancer under thiopurines [7]. The
frequency and type of side effects of drugs used for IBD
treatment are typically reported in the medical literature
on the basis of the use of single drugs [8]. However, in
daily practice, IBD drugs are frequently combined.
Examples include the use of combined therapy with aza-
thioprine and inﬂiximab that has been associated with
better clinical and endoscopic remission rates in CD
patients naive to treatment when combined with the single
use of either inﬂiximab and azathioprine and the combined
use of these substances in CD patients to reduce the
risk for anti-TNF-antagonist antibody formation [9,10].
aDivision of Gastroenterology and Hepatology, bDivision of Pediatric
Gastroenterology and Nutrition, cDivision of Visceral Surgery, Lausanne University
Hospital, University of Lausanne, dInstitute of Social and Preventive Medicine
(IUMSP), Lausanne University Hospital, eCrohn and Colitis Center, Clinique La
Source, Lausanne, fInstitute of Social and Preventive Medicine, University of Bern,
gDivision of Gastroenterology and Hepatology, University Hospital Bern, Bern,
hSwiss EoE Center, Pediatrician Römerhof, Olten, iDivision of Gastroenterology
and Hepatology, University Hospital Zurich, jDivision of Gastroenterology and
Hepatology, Triemli Hospital and kGastroCenter Hirslanden Zurich, Zurich,
Switzerland
Correspondence to Alain M. Schoepfer, MD, Division of Gastroenterology and
Hepatology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon
44, 1011 Lausanne, Switzerland
Tel: + 41 21 314 2394; fax: + 41 21 314 4718; e-mail: alain.schoepfer@chuv.ch
Supplemental Digital Content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions of this
article on the journal’s website, www.eurojgh.com.
Received 9 July 2017 Accepted 4 October 2017
European Journal of Gastroenterology & Hepatology 2018, 00:000–000
Keywords: drug-related side effect, inﬂammatory bowel disease therapy,
inﬂammatory bowel disease
’Original article
0954-691X Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MEG.0000000000001078 1
Copyright r 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
However, the multiplicity of treatments may increase the
likelihood of development of side effects. For instance,
although monotherapy with adalimumab was not asso-
ciated with an increase in malignancies, combination
therapy with azathioprine clearly was [11].
Given the fact that there is a paucity of cohort studies
providing a global view of the type and frequency of drug-
related adverse events, we initiated this investigation to
address the following questions: ﬁrst, what is the frequency
and type of adverse events related to single drug treatments
in IBD patients? Second, what is the frequency of adverse
events related to the use of multiple (at least two) drug
treatments in IBD patients? Third, do particular risk fac-
tors besides the use of the drug itself exist that can be
linked to the occurrence of drug-related side effects?
Patients and methods
Patients
The Swiss Inﬂammatory Bowel Disease Cohort (SIBDC)
has been including IBD patients from all regions of
Switzerland since 2006. The SIBDC is supported by the
Swiss National Science Foundation and is approved by
local ethics committees [12]. For inclusion, patients have to
be at least 18 years old and need to provide written
informed consent. In addition, a permanent residence status
in Switzerland and/or Swiss health insurance coverage is
mandatory. Patients can be included in the cohort if a
diagnosis of CD, UC, or IBD unclassiﬁed has been estab-
lished at least 4 months before inclusion, or if they had at
least one episode of symptom recurrence [12]. Patients are
prospectively included if the diagnosis of IBD has been
established in 2006 or later; a retrospective inclusion of
patients diagnosed with IBD in 2005 and earlier is also
possible. At the time of inclusion, patients undergo a
thorough clinical and laboratory assessment. Clinical,
socioeconomic, and psychosocial data are collected. The
treating physicians complete physician-reported outcomes,
whereas the patients complete patient-reported outcomes
such as questionnaires on quality of life. Disease location is
recorded according to the Montréal classiﬁcation [13].
After enrollment, patients and physicians complete a yearly
follow-up questionnaire. Patients included in this study
were recruited in the following settings of care: 61% in
university hospitals, 13% in large nonuniversity hospitals,
6% in regional hospitals, and 20% in private practices.
Methods
The collected data were entered into a Microsoft Access
database (Access 2000; Microsoft Switzerland Ltd Liab.
Co., Wallisellen, Switzerland) at the datacenter of the
SIBDC, which is located at the Institute of Social and
Preventive Medicine, University of Lausanne. For the pur-
pose of this manuscript, the analysis was based on the
validated data obtained from IBD patients enrolled into the
SIBDC between May 2006 and April 2016 (10 years per-
iod). Data were extracted from physician questionnaires that
record on-treatment adverse events that required drug ces-
sation during the entire disease history. The following drug
categories were analyzed: aminosalicylates [5-aminosalicylic
acid (5-ASA)], steroids [topical (budesonide capsules or
enema) and systemic steroids were analyzed separately],
thiopurines, methotrexate, TNF-antagonists, and calcineurin
inhibitors (tacrolimus, cyclosporine). The follow-up ques-
tionnaires of the cohort do not assess the time interval
(months) at which the particular drug was administered, and
they also did not capture any follow-up information after a
particular adverse event had developed that led to drug
cessation.
Statistical analysis
Data were retrieved from the database of the SIBDC at the
Institute of Social and Preventive Medicine of University
of Lausanne. All statistical analyses were carried out by
the cohort statistician (N.F.) using the statistical package
program Stata (version 12.1; StataCorp., College Station,
Texas, USA). Quantitative data distribution was analyzed
using normal-QQ-plots. Results of quantitative data are
presented either as median plus interquartile ranges (for
data with a non-Gaussian distribution) or as mean ± SD
and range (for normally distributed data). Categorical
data were summarized as the percentage of the group
total. For quantitative data, differences in distribution
between two groups were evaluated using either the
Wilcoxon–Mann–Whitney rank test (for data with a non-
Gaussian distribution) or the Student t-test (for normally
distributed data). For categorical outcomes, differences in
the observed frequencies between groups were compared
using the χ2-test or the exact Fisher’s test for groups with a
small number of observations (n< 20). A Bonferroni
adjustment was used throughout in case of multiple testing.
A P-value of less than 0.05 was considered statistically
signiﬁcant. Stepwise multiple logistic regression modeling
was performed to evaluate the association between poten-
tial risk factors and the appearance of drug-related adverse
events leading to drug cessation. The variables tested as
potential risk factors were sex, age at the time of IBD
diagnosis, disease duration, IBD family history, presence of
extraintestinal manifestations (EIM), smoking status, BMI,
IBD-related surgery, and the number of concomitantly used
IBD drugs. In a ﬁrst step, the potential risk factors were
each tested separately. In a second step, all risk factors with
a P-value less than 0.2 were entered together into the
multivariate logistic regression model.
Results
Baseline characteristics
A total of 3192 patients were included, of whom 1792
(56.1%) had CD, 1322 (41.4%) had UC, and 78 (2.5%) had
IBD unclassiﬁed. Of 3138 patients treated with IBD drugs,
2129 (67.8%) presented with one or several drug-related side
effects that required drug cessation (Table 1). Disease duration
of IBD patients with and without treatment adverse events
was similar (median 12 years for both groups, P=0.675). The
age at enrollment into the SIBDC was again similar between
the groups with and without therapy adverse events that
necessitated a drug cessation. No relevant differences were
noted with respect to disease location for CD and UC between
the groups with and without treatment adverse events. It is
noteworthy that IBD patients who experienced drug-related
side effects underwent combined treatments with two and
more IBD drugs signiﬁcantly more frequently compared with
IBD patients without drug-related side effects (P<0.001).
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Frequencies and types of inﬂammatory bowel disease
drug-related adverse events
In Table 2, we present the IBD drug-related adverse events
during the entire disease course stratiﬁed according to IBD
Table 1. Clinical characteristics of patients
Patients with
adverse drug
event
Patients
without
adverse drug
event
Patients
never treated
with any IBD
drugs P-valuea
Total number of all IBD
patients
2129 (66.7) 1009 (31.6) 54 (1.7) –
Sex – <0.001
Male 1127 (52.9) 456 (45.2)
Female 1002 (47.1) 553 (54.8)
Diagnosis – <0.001
CD 1140 (53.6) 633 (62.7)
UC 936 (44.0) 355 (35.2)
IBDU 53 (2.5) 21 (2.1)
Age at diagnosis
(years)
– 0.382
Median 25 28
IQR 21–37 20–39
Range 1–83 5–80
Age at enrollment
(years)
– 0.195
Median 40 39
IQR 29–52 29–51
Range 18–88 18–82
Age at latest follow-
up (years)
– 0.656
Median 45 43
IQR 33–57 33–56
Range 18–93 18–86
Disease duration
(years)
– 0.675
Median 12 12
IQR 6–20 7–19
Range 0–59 0–57
Smoking status at
diagnosis
– 0.013
Nonsmoker 1320 (62.0) 579 (57.4)
Smoker 718 (33.7) 394 (39.1)
Unknown 91 (4.3) 36 (3.5)
Number of IBD
treatments
– <0.001
1 326 (15.3) 12 (1.2)
2 585 (27.5) 62 (6.1)
3 or more 1218 (57.2) 935 (92.7)
CD patients 1140 (63.6) 633 (35.3) 19 (1.1)
Sex – <0.001
Male 584 (51.2) 261 (41.2)
Female 556 (48.8) 372 (58.8)
Age at diagnosis
(years)
– 0.738
Median 26 25
IQR 20–36 20–37
Range 1–81 5–80
Age at enrollment
(years)
– 0.175
Median 39 38
IQR 28–51 27–50
Range 18–88 18–81
Age at latest follow-
up (years)
– 0.426
Median 44 42
IQR 32–57 32–55
Range 18–93 18–86
Disease duration
(years)
– 0.741
Median 13 12
IQR 7–22 7–20
Range 0–59 0–57
Smoking status at
diagnosis
– 0.026
Nonsmoker 577 (50.6) 292 (46.1)
Smoker 507 (44.5) 320 (50.6)
Unknown 56 (4.9) 21 (3.3)
Number of IBD
treatments
– <0.001
1 138 (12.1) 2 (0.3)
2 294 (25.8) 38 (6.0)
3 or more 708 (62.1) 593 (93.7)
Table 1. (Continued)
Patients with
adverse drug
event
Patients
without
adverse drug
event
Patients
never treated
with any IBD
drugs P-valuea
Disease location at
diagnosis
– 0.445
L1 (ileal) 261 (22.9) 157 (24.8)
L2 (colonic) 251 (22.0) 116 (18.3)
L3 (ileocolonic) 502 (44.0) 291 (46.0)
L4 only (upper GI) 9 (0.8) 5 (0.8)
Unknown/unclear 117 (10.3) 64 (10.1)
Disease location at
the latest follow-up
– 0.837
L1 (ileal) 339 (29.7) 194 (30.7)
L2 (colonic) 0.391 (34.3) 206 (32.5)
L3 (ileocolonic) 365 (32.0) 202 (31.9)
L4 only (upper GI) 24 (2.1) 17 (2.7)
Unknown/unclear 21 (1.8) 14 (2.2)
UC/IBDU patients [n (%)] 989 (70.6) 376 (26.9) 35 (2.5)
Sex – 0.314
Male 543 (54.9) 195 (51.9)
Female 446 (45.1) 181 (48.1)
Age at diagnosis
(years)
– 0.857
Median 31 31
IQR 23–40 23–42
Range 3–83 10–78
Age at enrollment
(years)
– 0.773
Median 41 42
IQR 31–52 31–53
Range 18–85 18–82
Age at latest follow-
up (years)
– 0.352
Median 45 46
IQR 35–56 36–58
Range 18–89 18–85
Disease duration
(years)
– 0.657
Median 11 11
IQR 6–18 7–17
Range 0–50 0–52
Smoking status at
diagnosis
– 0.756
Nonsmoker 743 (75.1) 287 (76.3)
Smoker 211 (21.3) 74 (19.7)
Unknown 35 (3.5) 15 (4.0)
Number of IBD
treatments
– <0.001
1 188 (19.0) 10 (2.7)
2 291 (29.4) 24 (6.4)
≥3 510 (51.6) 342 (91.0)
Disease location at
diagnosis
– 0.002
Pancolitis 366 (37.0) 155 (41.2)
Left-sided colitis 315 (31.9) 121 (32.2)
Proctitis 219 (22.1) 52 (13.8)
Unknown/unclear 89 (9.0) 48 (12.8)
Disease location at
enrollment
– 0.033
Pancolitis 373 (37.7) 156 (41.5)
Left-sided colitis 368 (37.2) 154 (41.0)
Proctitis 228 (23.1) 60 (16.0)
Unknown/unclear 20 (2.0) 6 (1.6)
Data are presented as n (%).
Disease location is indicated according to the Montréal classiﬁcation [13].
CD, Crohn’s disease; IBD, inﬂammatory bowel disease; IBDU, inﬂammatory bowel
disease of undetermined origin; IQR, interquartile range; UC, ulcerative colitis.
aThe P-value refers to the comparison between IBD patients with versus without
adverse drug event.
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type. The lowest frequency of IBD drug adverse events
necessitating drug cessation was observed for topical and
systemic steroids (5.3 and 4.7%), followed by aminosali-
cylates (7.9%). The frequency of drug-related side effects
necessitating treatment discontinuation for azathioprine,
mercaptopurine, and methotrexate was 25.1, 30.1, and
19.8%, respectively. Figure 1 shows the frequency of drug-
related side effects necessitating drug cessation in IBD
patients during their entire disease history, stratiﬁed
according to IBD diagnosis.
A detailed overview of the distinct types of IBD drug-
related adverse events, stratiﬁed according to distinct drug
classes and IBD diagnosis, is available in Supplementary
Table 1 (Supplemental digital content 1, http://links.lww.com/
EJGH/A258). Use of 5-ASA was generally associated with a
low prevalence of adverse drug reactions that necessitated drug
cessation. Nephritis requiring 5-ASA cessation was observed in
0.3% of patients. Steroids had to be stopped in 0.2% of treated
patients because of osteopenia/osteoporosis, in 0.2% of treated
patients because of psychological intolerance, and in 0.1% of
steroid-treated patients because of diabetes. Mercaptopurine
had to be discontinued because of leukopenia, hepatotoxicity,
and pancreatitis in 2.7, 2.3, and 1.1% of treated patients,
respectively. Azathioprine had to be stopped because of leu-
kopenia, hepatotoxicity, and pancreatitis in 1.2, 0.8, and
1.2%, respectively. No lymphoma was reported in patients
being treated with thiopurines. In 0.3% of patients treated with
methotrexate, a discontinuation of therapy because of liver
ﬁbrosis/cirrhosis was reported. Gastrointestinal intolerance
necessitated methotrexate cessation in 4.8% of treated patients.
Cyclosporine had to be stopped in 3.8% of treated patients
because of renal hypertension. Hypersensitivity reactions
necessitating drug cessation were documented in 2.5% of
patients under inﬂiximab compared with 1.0% of patients
under adalimumab and 1.8% of patients under certolizumab.
We identiﬁed one patient with pulmonary tuberculosis who
required inﬂiximab cessation. There was no tuberculosis case
requiring cessation of treatment with adalimumab and certo-
lizumab, respectively. The overall rate of infections necessitat-
ing the cessation of TNF-antagonists was very low [0%, 95%
conﬁdence interval (CI): 0–1.7%]. Injection-site reactions
required adalimumab discontinuation in 0.2% of treated
patients. The three different TNF-antagonists had a similar
distribution in the frequency of other adverse events such as
asthenia, fever, headache, arthralgia, nausea, or abdominal
pain requiring drug cessation.
Frequency and type of inﬂammatory bowel disease drug-
related adverse events in patients under combined
regimens
We analyzed the prevalence of drug-related side effects
necessitating drug discontinuation in relation to the num-
ber of IBD drugs used. The majority of drug-related side
effects that required drug cessation developed in IBD
patients under monotherapy with an IBD drug (Table 3).
The number of concomitantly used IBD drugs increased
the risk for the development of IBD drug-related adverse
events that required IBD drug cessation (Table 4). When
looking at all IBD patients together, patients under IBD
drug monotherapy had a cumulative frequency of 10.3%
of drug-related side effects that necessitated drug cessation.
This risk increased to 19.0% in IBD patients being treated
with two IBD drugs and 26.0% in IBD patients being
treated with at least three IBD drugs (Table 4). CD patients
more frequently developed IBD drug-related side effects
that necessitated drug cessation compared with UC
patients (12.5 vs. 6.8% for patients under monotherapy,
P= 0.001; 21.3 vs. 15.2% for patients under combined
therapy with two drugs, P=0.010; and 33.3 vs. 21.1% for
patient treated with at least three IBD drugs, P= 0.002).
Figure 2 shows the frequency of drug-related adverse
events requiring IBD drug cessation in relation to the
number of concomitantly used IBD drugs.
Systematic analysis of risk factors for inﬂammatory bowel
disease drug-related adverse events necessitating
treatment discontinuation
We systematically analyzed the risk for the occurrence of
IBD drug-related side effects necessitating cessation of
Table 2. Frequency of adverse drug events necessitating drug discontinuation in inﬂammatory bowel disease patients
Drug category CD [n (%)] UC [n (%)] IBDU [n (%)] Total [n (%)]
Aminosalicylates 70/1033 (6.8) 108/1243 (8.7) 6/67 (9.0) 184/2343 (7.9)
Budesonide 47/847 (5.6) 26/532 (4.9) 2/30 (6.7) 75/1409 (5.3)
Prednisone 63/1292 (4.9) 42/941 (4.5) 2/54 (3.7) 107/2287 (4.7)
Azathioprine 339/1337 (25.4) 179/733 (24.4) 13/48 (27.1) 531/2118 (25.1)
6-Mercaptopurine 79/253 (31.2) 44/154 (28.6) 2/8 (25.0) 125/415 (30.1)
Methotrexate 74/379 (19.5) 24/112 (21.4) 2/14 (14.3) 100/505 (19.8)
Cyclosporine 3/27 (11.1) 14/95 (14.7) 0/4 (0.0) 17/126 (13.5)
Inﬂiximab 201/938 (21.4) 71/401 (17.7) 10/33 (30.3) 282/1372 (20.6)
Adalimumab 74/481 (15.4) 11/109 (10.1) 2/15 (13.3) 87/605 (14.4)
Certolizumab 37/231 (16.0) 0/11 (0.0) 0/4 (0.0) 37/246 (15.0)
CD, Crohn’s disease; IBDU, inﬂammatory bowel disease of undetermined origin; UC, ulcerative colitis.
Fig. 1. Frequency of drug adverse events necessitating drug cessation in
inﬂammatory bowel disease patients during their entire disease history stratiﬁed
according to inﬂammatory bowel disease diagnosis. 5-ASA, 5-aminosalicylic
acid; CD, Crohn’s disease; CI, conﬁdence interval; UC, ulcerative colitis.
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treatment by the means of logistic regression modeling. We
ﬁrst analyzed the risk factors for IBD drug-related side
effects in the entire IBD population (Table 5). In the uni-
variate logistic regression model, we found that female sex,
CD diagnosis, the presence of EIM, IBD-related surgery,
and the number of concomitantly used IBD drugs were
associated signiﬁcantly with an increased risk for the
occurrence of IBD drug-related side effects necessitating
discontinuation of drug. There was also a trend for disease
duration more than 10 years to be associated with the risk
of drug-related adverse events requiring discontinuation of
drug. All factors from the univariate analysis with a
P-value less than 0.2 were entered into the multivariate
model. In the multivariate model, we identiﬁed CD diag-
nosis [odds ratio (OR)= 1.361], presence of EIM
(OR=2.262), IBD-related surgery (OR=1.419), and the
increasing number of concomitantly used IBD drugs
(OR=2.007 for two concomitantly used IBD drugs;
OR=3.225 for at least three concomitantly used IBD
drugs) to be associated signiﬁcantly with the occurrence of
IBD drug-related adverse events that necessitated drug
cessation. The use of at least three concomitantly used IBD
drugs showed the strongest association with IBD drug-
related adverse events necessitating drug cessation among
all the analyzed risk factors.
The analyses for CD and UC patients are shown in
Supplementary Tables 2 and 3 (Supplemental digital con-
tent 1, http://links.lww.com/EJGH/A258). In CD patients,
the multivariate model identiﬁed the presence of EIM
(OR=2.556), IBD-related surgery (OR=1.367), and the
number of concomitantly used IBD drugs (OR= 1.906 for
two concomitantly used IBD drugs; OR=3.589 for at least
three concomitantly used IBD drugs) to be associated sig-
niﬁcantly with IBD drug-related side effects requiring drug
cessation. Again, the use of at least three concomitantly
used IBD drugs showed the strongest association with IBD
drug-related adverse events necessitating drug cessation
among all the analyzed risk factors (Supplementary
Table 3. Frequency of adverse events depending on the type of drug
and the number of concomitant treatments used
CD patients
[n (%)]
UC patients
[n (%)]
All patients
[n (%)]
5-ASA side effect
Under monotherapy 15 (93.8) 21 (60.0) 36 (70.6)
Under therapy with two drugs 1 (6.2) 12 (34.3) 13 (25.5)
Under therapy with at least three
drugs
0 (0.0) 2 (5.7) 2 (3.9)
Cyclosporine side effect
Under monotherapy 0 (0.0) 2 (25.0) 2 (20.0)
Under therapy with two drugs 1 (50.0) 4 (50.0) 5 (50.0)
Under therapy with at least three
drugs
1 (50.0) 2 (25.0) 3 (30.0)
Azathioprine side effect
Under monotherapy 70 (89.6) 35 (55.6) 105 (69.5)
Under therapy with two drugs 17 (19.3) 21 (33.3) 38 (25.2)
Under therapy with at least three
drugs
1 (1.1) 7 (11.1) 8 (5.3)
6-Mercaptopurine side effect
Under monotherapy 24 (77.4) 14 (63.6) 38 (71.7)
Under therapy with two drugs 6 (19.4) 6 (27.3) 12 (22.6)
Under therapy with at least three
drugs
1 (3.2) 2 (9.1) 3 (5.7)
Methotrexate side effect
Under monotherapy 24 (66.7) 6 (50.0) 30 (62.5)
Under therapy with two drugs 9 (25.0) 2 (16.7) 11 (22.9)
Under therapy with at least three
drugs
3 (8.3) 4 (33.3) 7 (14.6)
Inﬂiximab side effect
Under monotherapy 96 (76.2) 27 (56.3) 123 (70.7)
Under therapy with two drugs 27 (21.4) 15 (31.3) 42 (24.1)
Under therapy with at least three
drugs
2 (2.4) 6 (12.5) 9 (5.2)
Adalimumab side effect
Under monotherapy 37 (72.6) 5 (55.6) 42 (70.0)
Under therapy with two drugs 12 (23.5) 3 (33.3) 15 (25.0)
Under therapy with at least three
drugs
2 (3.9) 1 (11.1) 3 (5.0)
Certolizumab side effect
Under monotherapy 16 (51.6) 0 (0.0) 16 (51.6)
Under therapy with two drugs 14 (45.2) 0 (0.0) 14 (45.2)
Under therapy with at least three
drugs
1 (3.2) 0 (0.0) 1 (3.2)
Budesonide side effect
Under monotherapy 5 (50.0) 1 (20.0) 6 (40.0)
Under therapy with two drugs 4 (40.0) 2 (40.0) 6 (40.0)
Under therapy with at least three
drugs
1 (10.0) 2 (40.0) 3 (20.0)
Prednisone side effect
Under monotherapy 9 (60.0) 5 (62.5) 14 (60.9)
Under therapy with two drugs 5 (33.3) 2 (25.0) 7 (30.4)
Under therapy with at least three
drugs
1 (6.7) 1 (12.5) 2 (8.7)
5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; UC, ulcerative colitis.
Table 4. Frequency of inﬂammatory bowel disease drugs-related adverse events in relation to the number of concomitantly used drugs
CD patients [n (%)] UC patients [n (%)] All patients [n (%)]
No side effects Side effects No side effects Side effects No side effects Side effects
Never treated with combo therapy 664 (87.5) 95 (12.5) 441 (93.2) 32 (6.8) 1105 (89.7) 127 (10.3)
Treated with two IBD drugs concomitantly 561 (78.7) 152 (21.3) 379 (84.8) 68 (15.2) 940 (81.0) 220 (19.0)
Treated with at least three IBD drugs concomitantly 134 (66.7) 67 (33.3) 239 (78.9) 64 (21.1) 373 (74.0) 131 (26.0)
CD, Crohn’s disease; IBD, inﬂammatory bowel disease; UC, ulcerative colitis.
Fig. 2. Frequency of drug adverse events necessitating drug cessation in
IBD patients in relation to the number of concomitantly used IBD drugs. CD,
Crohn’s disease; CI, conﬁdence interval; IBD, inﬂammatory bowel disease;
UC, ulcerative colitis.
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Table 3, Supplemental digital content 1, http://links.lww.
com/EJGH/A258).
In UC patients, the multivariate model identiﬁed
the presence of EIM (OR= 1.937), IBD-related surgery
(OR= 1.506), and the number of concomitantly used
IBD drugs (OR= 2.229 for two concomitantly used IBD
drugs; OR= 2.991 for at least three concomitantly used
IBD drugs) to be associated signiﬁcantly with IBD drug-
related side effects requiring drug cessation. Smoking
was identiﬁed as a protective factor (OR= 0.525) for
IBD drug-related side effects.
Discussion
We present data of a large national cohort study evaluat-
ing the frequency and type of IBD drug-related side effects
that necessitated treatment discontinuation. Our study
yielded several results that are clinically relevant. First,
over a median disease duration of 12 years, the majority
(67.8%) of patients experienced IBD drug-related side
effects that required treatment discontinuation. Second,
drug-related side effects requiring treatment discontinua-
tion were most frequently observed for thiopurines, fol-
lowed by methotrexate, TNF-antagonists, cyclosporine,
5-ASA, and steroids. Third, the number of concomitantly
used IBD drugs was the strongest predictor for experien-
cing IBD drug-related side effects necessitating treatment
discontinuation.
We ﬁrst discuss drug-related side effects necessitating
treatment cessation according to the observed frequencies
of the different drugs. Azathioprine and mercaptopurine
are steroid-sparing drugs that have been used to treat CD
and UC for over 50 years [14]. We found a frequency of
drug-related side effects requiring treatment cessation in
25.1% of IBD patients treated with azathioprine and in
30.1% of patients treated with 6-mercaptopurine (6-MP).
Leukopenia, pancreatitis, and gastrointestinal intolerance
were the dominant reasons for thiopurine cessation. Our
data are in agreement with the study by Chaparro et al.
[15], who evaluated the incidence of thiopurine-related
adverse events in 3931 patients with a median follow-up of
44 months (range: 0–420 months). They observed a
cumulative incidence of adverse events of 26%, with an
annual risk of 7% for patient-year of treatment. The most
frequent adverse events were nausea (8%), hepatotoxicity
(4%), myelotoxicity (4%), and pancreatitis (4%). A total
of 17% of patients had to discontinue thiopurines because
of these adverse events [15]. The higher frequency of
adverse events leading to thiopurine cessation in the
SIBDC can be explained by the longer follow-up in our
cohort. The fact that we observed 6-MP-related side effects
leading to drug cessation in 30.1% of treated patients
represents a selection bias as 6-MP is mostly used in
patients who have already experienced an adverse drug
event under azathioprine.
We observed methotrexate-related adverse events lead-
ing to drug cessation in 19.8% of treated patients.
Gastrointestinal intolerance (nausea, vomiting, elevated
liver enzymes) was the dominant reason (27%) to dis-
continue methotrexate. Our ﬁndings are in agreement with
the literature reporting that the typical side effects of
methotrexate therapy include liver toxicity, dyspnea,
Table 5. Logistic regression modeling to identify the factors associated with drug-related adverse events in all inﬂammatory bowel disease patients
during the follow-up period
Univariate model Multivariate model
OR 95% CI P-value OR 95% CI P-value
Sex
Male 1 (ref) – – 1 (ref) – –
Female 1.273 1.033–1.568 0.024 1.172 0.941–1.457 0.157
Age at diagnosis (years)
<40 1 (ref) – –
≥40 1.073 0.833–1.382 0.586
Diagnosis
UC 1 (ref) – – 1 (ref) – –
CD 1.541 1.239–1.916 <0.001 1.361 1.057–1.751 0.017
Disease duration (years)
≤10 1 (ref) – – 1 (ref) – –
>10 1.168 0.947–1.442 0.147 0.919 0.732–1.155 0.470
IBD family history
No 1 (ref) – –
Yes 0.976 0.717–1.329 0.879
EIM
No 1 (ref) – – 1 (ref) – –
Yes 2.615 2.091–3.271 <0.001 2.262 1.794–2.852 <0.001
Cigarette smoking at diagnosis
Nonsmoker 1 (ref) – –
Smoker 1.074 0.867–1.329 0.515
BMI
<30 1 (ref) – –
≥30 1.025 0.714–1.474 0.892
IBD-related surgery
No 1 (ref) – – 1 (ref) – –
Yes 1.662 1.344–2.054 <0.001 1.419 1.107–1.818 0.006
Ever treated with combo therapy
Never 1 (ref) – – 1 (ref) – –
2-therapy combo 2.141 1.664–2.755 <0.001 2.007 1.553–2.595 <0.001
3+ -therapy combo 3.154 2.367–4.204 <0.001 3.225 2.391–4.349 <0.001
CD, Crohn’s disease; CI, conﬁdence interval; EIM, extraintestinal manifestation; IBD, inﬂammatory bowel disease; OR, odds ratio; UC, ulcerative colitis.
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nausea, vomiting, fatigue, and neutropenia [16]. Goodman
et al. [17] found that 30% of patients treated with
methotrexate for at least 5 years discontinued therapy because
of adverse effects. Other studies reported a side effect rate as
low as 17%, with withdrawal of methotrexate in only 8% of
patients [18]. The rate of discontinuation for methotrexate
observed in our cohort is also between these values. It is
noteworthy that higher prevalence rates for methotrexate-
related adverse events were observed (74 vs. 38%) in patients
who did not receive folic acid supplementation [18]. The
questionnaires of the SIBDC did not systematically assess
concomitant supplementation with folic acid.
Monoclonal antibodies directed against TNF-α are used
to treat IBD patients with moderate-to-severe clinical
activity not responding to conventional medical therapy.
Inﬂiximab, adalimumab, and certolizumab pegol are
approved for the induction and maintenance of remission
in CD [19–21], whereas inﬂiximab, adalimumab, and
golimumab are approved for the induction and main-
tenance of remission in UC [22–24]. Well-known adverse
events of anti-TNF therapy are an increased risk of serious
and opportunistic infections, infusion reactions (for
inﬂiximab), skin reactions (for adalimumab and certoli-
zumab pegol), autoimmunity, heart failure, and risk of
melanoma. In our cohort, we observed a discontinuation
rate because of side effects of inﬂiximab in 20.6%, certo-
lizumab pegol in 15%, and adalimumab in 14.4% of
patients, respectively. Opportunistic infections were rarely
reported in our cohort (< 1% of treated patients).
However, TNF-antagonist therapy is well known to be
associated with an increased risk of severe and opportu-
nistic infections in patients with IBD [25]. An analysis
from the Crohn’s Therapy, Resource, Evaluation, and
Assessment Tool (TREAT) registry found that inﬂiximab
exposure was associated with severe infections [hazard
ratio (HR)=1.4, 95% CI: 1.1–1.8] even after adjusting for
other factors such as disease activity, steroid use, and
narcotic use [26]. In addition to severe infections, IBD
patients exposed to TNF-antagonists are also at risk of
developing opportunistic infections. A recent meta-analysis
of 22 randomized-controlled trials found that opportu-
nistic infections developed in 0.9% of patients receiving
TNF-antagonist therapy versus 0.3% of patients under
placebo (relative risk=2.1, 95% CI: 1.1-3.9) [27].
Infusion reactions under inﬂiximab leading to drug dis-
continuation were observed in 2.5% of treated IBD
patients in the SIBDC. These data are in agreement with
the literature showing that infusion reactions occur with
3–17% of inﬂiximab infusions [28]. As shown by Cheifetz
et al. [29] in a cohort of 165 patients receiving 479
infusions over a 3-year period, the majority of infusion
reactions are mild and rarely lead to inﬂiximab dis-
continuation. We found injection-site reactions leading to
drug discontinuation in 0.2% of adalimumab-treated
patients and in none of the patients treated with certoli-
zumab pegol. Our ﬁndings are in agreement with the lit-
erature showing that injection-site reactions can occur in
up to 5% of adalimumab-treated patients [27]. In contrast
to this ﬁnding, patients receiving certolizumab pegol had a
lower rate of injection-site reactions than patients receiving
placebo (3 vs. 14%) [28]. Psoriasiform and eczematiform
lesions may also develop under TNF-antagonist treatment
[30]. We found that 3.5, 2.2, and 4.2% of IBD patients
treated with inﬂiximab, adalimumab, and certolizumab
pegol, respectively, discontinued their drug because of skin
reactions. These data are again in agreement with studies
showing an incidence of eczematiform and psoriatic
lesions to be 9–16% [31]. Of these, up to 34% of patients
ultimately discontinue TNF-antagonist therapy [32].
Cyclosporine and tacrolimus are effective in inducing
clinical response and remission in UC patients with severe
disease [33]. The main adverse reactions include renal
dysfunction, tremor, hirsutism, hypertension, gum hyper-
plasia, and gastrointestinal intolerance [33]. In our cohort,
we found that 13.5% of patients treated with cyclosporine
and/or tacrolimus, respectively, had to discontinue treat-
ment because of adverse events. The most frequently cited
reasons for drug discontinuation were hypertension and
gastrointestinal intolerance.
Aminosalicylates (5-ASA) are considered to be relatively
safe and have similar adverse events compared with pla-
cebo. Most frequent adverse events are diarrhea (3%),
headache (2%), nausea (2%), rash (1%), and thrombo-
cytopenia (<1%) [6]. In our cohort, a total of 7.9% of
patients discontinued their 5-ASA treatment because of
adverse events. The most frequent reasons for 5-ASA dis-
continuation were nausea/diarrhea (0.9% of all 5-ASA-
treated patients), gastrointestinal intolerance (0.4%), and
nephritis (0.3%).
Systemic glucocorticoids are effective in inducing
remission in both CD and UC, whereas they are ineffective
in the maintenance of remission in both diseases [34,35].
However, their use is limited by their frequent side effects
[36]. The most frequent side effects occur in the skin, such
as thinning of the skin or purpura. Steroids can induce
both osteoporosis and osteonecrosis. Furthermore, they
increase the susceptibility to various fungal, viral, and
bacterial infections. Steroids can cause various psychologic
complications such as depression, insomnia, or euphoria.
Other potential side effects include myopathy, cushingoid
features, redistribution of body fat, hyperlipidemia,
hyperglycemia or overt diabetes, and ophthalmologic
complications such as cataract or glaucoma. Despite the
high prevalence of steroid-related side effects described in
the literature, only 5.3 and 4.7% of patients treated with
topical and systemic steroids discontinued these drugs
because of side effects in our cohort. The most frequent
reasons for glucocorticosteroid discontinuation were
cushingoid features (0.6% of all steroid-treated IBD
patients), gastrointestinal intolerance (0.4% of all steroid-
treated IBD patients), osteoporosis/osteopenia (0.2%),
psychosis (0.2%), edema (0.2%), and diabetes (0.1% of all
steroid-treated IBD patients). We were intrigued that,
despite the large variety of possible side effects, the dis-
continuation rate for steroids in our cohort was even lower
than the one for 5-ASA. This ﬁnding might be explained by
the fact that steroids are typically used for induction of
response and remission and not for maintenance treat-
ments, which is in contrast to the use of the other drugs
described above.
We identiﬁed UC diagnosis (OR= 0.735), presence of
EIM (OR= 2.262), IBD-related surgery (OR=1.419), and
the increasing number of concomitantly used IBD drugs
(OR=2.007 for two concomitantly used IBD drugs;
OR=3.225 for at least three concomitantly used IBD
drugs) to be associated signiﬁcantly with the occurrence of
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IBD drug-related adverse events that necessitated drug
cessation. It is noteworthy that the use of at least three
concomitantly used IBD drugs showed the strongest
association with IBD drug-related adverse events necessi-
tating treatment discontinuation. The SONIC trial showed
that a greater proportion of immunomodulator and
biologic-naive patients with moderate-to-severe CD who
were treated with a combination of azathioprine and
inﬂiximab achieved steroid-free remission at 6 months
compared with patients treated with inﬂiximab or aza-
thioprine alone (75 vs. 44 vs. 30%) [9]. In this trial, the
rates of serious infections were similar between aza-
thioprine alone, inﬂiximab alone, and the combination
therapy (4.6, 4.9, and 3.9%) [9]. However, an analysis of
CD patients who were treated with steroids, immunomo-
dulators, and/or anti-TNF-α agents found that CD patients
receiving at least two of these drugs had higher rates of
infections including tuberculosis (HR=7.4; 95% CI:
2.1–26), candidiasis (HR=3.8; 95% CI: 2.0–7.6), and
herpes zoster (HR= 3.7; 95% CI: 1.8–7.5) compared with
control patients and patients receiving only one of these
drugs [26].
Our study does have strengths and some limitations as
well. We present data from a large national cohort with a
median disease duration of 12 years. We report on the fre-
quency and type of drug-related side effects necessitating
treatment discontinuation, which represents a strong out-
come. To the best of our knowledge, this is the ﬁrst large
cohort study that convincingly shows the increased risk
developing adverse drug events requiring treatment dis-
continuation when combining different IBD drugs. As a ﬁrst
limitation, the SIBDCS is not population based as 80% of
patients are recruited in a hospital setting and only 20% of
patients are recruited by gastroenterologists in private prac-
tice. Therefore, data cannot be generalized to the entire IBD
population. Second, the follow-up questionnaires of the
SIBDCS do not capture detailed information on the duration
of the different treatments, nor do they assess, for example,
blood levels of metabolites of azathioprines and neither drug
levels of TNF-antagonists. Third, data capture once a year
may also predispose to under-reporting of events.
Conclusion
Over a median disease duration of 12 years, two-thirds of
patients experienced IBD drug-related side effects that
required treatment discontinuation. Drug-related side effects
necessitating treatment discontinuation were most frequently
observed for thiopurines, followed by methotrexate, TNF-
antagonists, cyclosporine, 5-ASA, and steroids. The number
of concomitantly used IBD drugs was the strongest predictor
for experiencing IBD drug-related side effects necessitating
treatment discontinuation. Physicians involved in the care of
patients with IBD should maintain a high level of awareness
of the potential occurrence of drug-related side effects in the
follow-up of their patients, particularly when combining
different IBD drugs.
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